Journal of Clinical Oncology, Vol 2, 164-168, Copyright © 1984 by American Society of Clinical Oncology

ARTICLES

Randomized phase III trial of vinblastine, bleomycin, and cis- dichlorodiammine-platinum versus dacarbazine in malignant melanoma

SD Luikart, GT Kennealey and JM Kirkwood

A randomized phase III study was carried out in 57 patients with metastatic melanoma treated with either dacarbazine (DTIC) given intravenously (IV) daily for 10 days using light protection, or a combination of vinblastine IV on days 1 and 2, bleomycin by continuous IV infusion during days 1-5, and cisplatin by IV infusion on day 5 (VBD). Objective response rates were similar: 14% for dacarbazine and 10% for VBD. However, dacarbazine responses were associated with a trend toward longer progression-free intervals and longer survival. Toxicity was significantly greater in the VBD arm, and fatal in two patients. Dacarbazine was also associated with severe toxicity by the 10-day light-protected schedule used here. VBD is not as effective as previously reported, and dacarbazine remains a standard of therapy for metastatic melanoma.

This article has been cited by other articles:

				N. J. Ives, R. L. Stowe, P. Lorigan, and K. Wheatley Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 Patients J. Clin. Oncol., December 1, 2007; 25(34): 5426 - 5434. [Abstract] [Full Text] [PDF]

				P. B. Chapman, L. H. Einhorn, M. L. Meyers, S. Saxman, A. N. Destro, K. S. Panageas, C. B. Begg, S. S. Agarwala, L. M. Schuchter, M. S. Ernstoff, et al. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma J. Clin. Oncol., September 1, 1999; 17(9): 2745 - 2745. [Abstract] [Full Text] [PDF]